Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Ultra Low Doses of Dapagliflozin in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions
Type 2 Diabetes
Interventions
DRUG

dapagliflozin

Oral Solution, Oral, 0.001 mg, once on Day 1 only, 2 days

DRUG

dapagliflozin

Oral Solution, Oral, 0.01 mg, once on Day 1 only, 2 days

DRUG

dapagliflozin

Oral Solution, Oral, 0.1 mg, once on Day 1 only, 2 days

DRUG

dapagliflozin

Tablets, Oral, 0.3 mg, once on Day 1 only, 2 days

DRUG

dapagliflozin

Tablets, Oral, 1 mg, once on Day 1 only, 2 days

DRUG

dapagliflozin

Tablets, Oral, 2.5 mg, once on Day 1 only, 2 days

Trial Locations (1)

78744

Ppd Development, Lp, Austin

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

AstraZeneca

INDUSTRY